Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officer to lead the Company's clinical development programsEli Lilly and Celgene veteran Jose Igle ...

Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program ...

Former Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as President and Chief Development Officerto lead the Company’s clinical development programsEli Lilly and Celgene veteran Jose ...

On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients ...

DelveInsight's PLK-1 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging ...

UMB Bank NA filed suit against Bristol-Myers in 2021, alleging that the company intentionally slow-rolled the approval ...

For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...

Bristol Myers Squibb won a legal victory as a New York judge dismissed a $6.4 billion lawsuit filed by UMB Bank on behalf of ...

District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol ...

Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation company, today announced that it has appointed Jorge F. DiMartino, M.D., Ph.D., as Chief Medical Officer and Executive ...

The global deuterated drugs market, valued at US$ 334.0 million in 2023, presents a robust growth pattern. With a projected valuation of US$ 871.8 million by 2032 at a CAGR of 11.25%, the market is ...